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BACKGROUND: B7-H3 is a new member of the B7 ligand family and regulates T-cell responses in various conditions. However, the
role of B7-H3 in tumour immunity is largely unknown. The purpose of this study was to evaluate the clinical significance of
B7-H3 expression in human pancreatic cancer and the therapeutic potential for cancer immunotherapy.
METHODS: We investigated B7-H3 expression in 59 patients with pancreatic cancer by immunohistochemistry and real-time PCR.
Furthermore, we examined the anti-tumour effect of B7-H3-blocking monoclonal antibody in vivo in a murine pancreatic cancer
model.
RESULTS: Tumour-related B7-H3 expression was abundant in most human pancreatic cancer tissues and was significantly higher
compared with that in non-cancer tissue or normal pancreas. Moreover, its expression was significantly more intense in cases with
lymph node metastasis and advanced pathological stage. B7-H3 blockade promoted CD8
þ T-cell infiltration into the tumour and
induced a substantial anti-tumour effect on murine pancreatic cancer. In addition, the combination of gemcitabine with B7-H3
blockade showed a synergistic anti-tumour effect without overt toxicity.
CONCLUSION: Our data show for the first time that B7-H3 may have a critical role in pancreatic cancer and provide the rationale for
developing a novel cancer immunotherapy against this fatal disease.
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Pancreatic cancer is one of most aggressive and intractable human
malignant tumours and a leading cause of cancer-related deaths
worldwide (Li et al, 2004; Laheru and Jaffee, 2005). Owing to its
extremely high malignant potential, it is usually diagnosed at an
advanced stage and often recurs even after curative surgery
(Traverso, 2006). Although recent significant advances in cancer
therapy, including the introduction of new chemotherapeutic
agents, have made a significant impact on the overall survival of
pancreatic cancer patients, complete cure is very rare and the
incidence rates are almost equal to mortality rates (Burris et al,
1997; Li et al, 2004; Laheru and Jaffee, 2005). Therefore, novel
approaches against pancreatic cancer need to be developed and
established to improve patient prognosis.
B7-H3 (CD276) is a new member of the B7 family and shares
20–27% identical amino acids with other members (Chapoval
et al, 2001). B7-H3 is not expressed on quiescent lymphocytes and
can be induced in activated dendritic cells, monocytes, T cells, and
in some tumour cell lines (Chapoval et al, 2001; Sun et al, 2002;
Steinberger et al, 2004; Zhang et al, 2005). B7-H3 is thought to
serve as an accessory co-regulator of T-cell responses after initial
antigen priming. At present, there is no consensus with regard to
the physiological and pathological roles of B7-H3, as both
immunological stimulatory and inhibitory functions have been
described (Chapoval et al, 2001; Sun et al, 2002; Suh et al, 2003;
Castriconi et al, 2004; Prasad et al, 2004; Steinberger et al, 2004;
Wang et al, 2005; Zhang et al, 2005). It was originally identified as
a co-stimulatory molecule that promotes T-cell proliferation and
IFN-g production (Chapoval et al, 2001). The experimental
evidence that acute and chronic cardiac allograft rejection can be
reduced in B7-H3 knockout mice further supports a stimulatory
role for B7-H3 on T cells (Wang et al, 2005). By contrast, B7-H3
has been shown to impair type 1 T-helper cell responses and
inhibit cytokine production (Suh et al, 2003). In vivo antibody-
mediated blockade of B7-H3 in mice has been reported to enhance
T-cell activation and to lead to more severe forms of experimental
autoimmune encephalitis (Suh et al, 2003; Prasad et al, 2004). In
addition, B7-H3 has been implicated to confer protection from
natural killer (NK) cell-mediated cytolysis (Castriconi et al, 2004).
Therefore, it is likely that B7-H3 exerts dual functions under
certain circumstances.
In tumour immunity, the precise role of B7-H3 also remains
unclear. B7-H3 expression has been identified in several tumour
cell lines and in actual human tumour specimens, including gastric
cancer, non-small-cell lung cancer, and prostate cancer (Sun et al,
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s2006; Wu et al, 2006; Roth et al, 2007; Zang et al, 2007). Several
murine studies have shown that introduction of B7-H3 in tumour
cells and tissues by various methods activates tumour-specific
immunocompetent cells and promotes anti-tumour response,
thereby leading to rapid tumour regression, reduction of
metastasis, and prolongation of animal survival (Sun et al, 2003;
Luo et al, 2004, 2006; Lupu et al, 2006, 2007). In addition, high
intra-tumour B7-H3 expression was shown to correlate with better
prognosis in gastric cancer (Wu et al, 2006). These data suggested
that tumour-associated B7-H3 expression might promote immune
response as a positive regulator. By sharp contrast, the negative
role of B7-H3 expression has been reported in lung and prostate
cancers (Sun et al, 2006; Roth et al, 2007; Zang et al, 2007). In non-
small-cell lung cancer, B7-H3 expression was inversely correlated
with the number of tumour-infiltrating lymphocytes, and a high
B7-H3 expression was more common in patients with lymph node
metastasis (Sun et al, 2006). Furthermore, a strong intensity for
B7-H3 was significantly correlated with disease spread at the time
of surgery, as well as with increased risk of recurrence and poor
prognosis in prostate cancer (Roth et al, 2007; Zang et al, 2007). In
addition, 4Ig-B7-H3 (B7-H3 protein with four-Ig-like domains)
was identified in advanced stage neuroblastoma and has been
shown to exert a protective effect on neuroblastoma cells from
NK-mediated lysis (Castriconi et al, 2004). Thus, experimental and
clinical data are conflicting and the precise role of B7-H3 in
tumour immunity has not been fully elucidated yet.
In this study, we investigated the clinical significance of B7-H3
expression in human pancreatic cancer and the therapeutic
efficacy of targeting the B7-H3 pathway towards future clinical
application for the treatment of pancreatic cancer.
MATERIALS AND METHODS
Patients
We examined 59 patients with pancreatic cancer who underwent
surgery at the Department of Surgery, Nara Medical University,
between 1996 and 2004 (Table 1). The median age of the patients
was 66 years, with a range of 42–80 years. Tissues, both cancerous
and non-cancerous, were obtained from resected specimens and
were then rapidly frozen at  801C for storage until use. The
remainder of each specimen was fixed in 10% phosphate-buffered
formalin and embedded in paraffin. Pancreatic cancers were
classified according to the TNM staging system. Post-operative
pathological examinations have indicated metastasis in distant
lymph nodes (M1, Stage IV) in seven patients. Primary tumour
tissues from these patients were included for histological analysis
in this study. Follow-up was until death or December 2007. The
median follow-up for all patients was 14 months, with a range of
3–157 months. Most of the patients received systemic adjuvant
chemotherapy after surgery. Normal pancreatic tissues were
obtained from surgical specimens other than pancreatic cancer.
Written informed consent was obtained from all patients before
treatment, according to our institutional guidelines.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues of primary tumour
were cut into 5-mm sections, deparaffinised, and rehydrated in a
graded series of ethanol. Antigen retrieval was carried out by
heating tissue sections using a Target Retrieval Solution, pH 9.0
(DAKO, Tokyo, Japan). To block endogenous peroxidase, sections
were immersed in 3% solution of hydrogen peroxide in absolute
methanol for 10min at room temperature and washed thrice in
fresh PBS, each of 5min duration. Purified goat anti-human B7-H3
antibody (100mgml
 1; R&D Systems, Minneapolis, MN, USA)
diluted 1:10 with Antibody Diluent (DAKO) was added and
incubated overnight at 41C. Sections were washed thrice in PBS,
each of 5min duration, and then Histofine Simple Stain MAX PO
(G) (NICHIREI, Tokyo, Japan) was added and incubated at room
temperature for 30min. After washing thrice, the Histofine DAB
substrate kit (NICHIREI) was added and incubated at room
temperature for 20min. Sections were rinsed thrice in distilled
water, counterstained with haematoxylin, dehydrated in ethanol,
cleared in xylene, and coverslipped. For the staining of mouse
CD8
þ T cells, purified rabbit anti-CD8 antibody (Abcam, Tokyo,
Japan) diluted 1:250 with Antibody Diluent (DAKO) was used and
incubated overnight at 41C. Sections were washed thrice in PBS,
followed by incubation with the EnVision detection system
(DAKO), according to the instructions of the manufacturer.
Evaluation of immunostaining
Immunohistochemistry for B7-H3 was evaluated by authorised
pathologists who had no knowledge of the patients’ clinical status
and outcome. Each sample was thoroughly evaluated at a
magnification of  100. To count CD8
þ T cells in murine
pancreatic cancer tissue, three randomly selected areas were
counted at  200 magnification, and the average count was
calculated.
Extraction of total RNAs and real-time reverse-
transcriptase PCR analysis
Total RNA was isolated using RNAspin Mini (GE Healthcare,
Tokyo, Japan) and the first-strand cDNA was synthesised from
1mg RNA using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA), according to the
instructions of the manufacturer. Real-time quantitative PCR
analysis was carried out using an ABI Prism 7700 sequence
detector system (Applied Biosystems). All primer/probe sets were
purchased from Applied Biosystems. PCR was carried out using
the TaqMan Universal PCR Master Mix (Applied Biosystems)
using 1ml of cDNA in a 20ml final reaction volume. The PCR
thermal cycle conditions were as follows: initial step at 951C for
10min, followed by 40 cycles of 951C for 15s and 601C for 1min.
The expression level of the housekeeping gene b2-microglobulin
was measured as an internal reference with a standard curve to
Table 1 Clinicopathological characteristics according to tumor B7-H3
expression
B7-H3 intensity
Variable n None or weak (%) Strong (%) P-value
Tumour status
T1 3 1 (5.0) 2 (5.1) 0.646
T2 12 5 (25.0) 7 (18.0)
T3 26 10 (50.0) 16 (41.0)
T4 18 4 (20.0) 14 (35.9)
Nodal status
N0 26 13 (65.0) 13 (33.3) 0.020
N1 33 7 (35.0) 26 (66.7)
Metastatic status
M0 52 18 (90.0) 34 (87.2) 0.751
M1 7 2 (10.0) 5 (12.8)
Pathological stage
IA, IB 7 4 (20.0) 3 (7.7) 0.040
IIA 13 8 (40.0) 5 (12.8)
IIB 16 4 (20.0) 12 (30.8)
III 16 2 (10.0) 14 (35.9)
IV 7 2 (10.0) 5 (12.8)
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sdetermine the integrity of template RNA for all specimens. The
ratio of the mRNA level of each gene was calculated as follows:
(absolute copy number of each gene)/(absolute copy number of
b2-microglobulin).
Animal and cell line
Female C57BL/6 mice (8–12-weeks old) were obtained from CLEA
JAPAN (Tokyo, Japan). All mice were maintained under specific
pathogen-free conditions in the animal facility at Nara Medical
University. All experiments were conducted under a protocol
approved by our institutional review board. A murine pancreatic
adenocarcinoma, PAN02, was obtained from the DCTD Tumor
Repository, National Cancer Institute (Frederick, MD, USA). Cells
were grown in RPMI 1640 supplemented with 10% heat-inactivated
foetal bovine serum.
Animal experimental protocol
PAN02 was orthotopically implanted in the pancreas of syngeneic
C57BL/6 mice. The anti-mouse B7-H3-blocking monoclonal
Ab (MJ18, rat IgG1) was generated as previously described
(Nagashima et al, 2008). The day after tumour implantation,
mAb treatment was started. In the antibody treatment arm, mice
were intraperitoneally injected with 0.3mg of MJ18 every other day
for 3 weeks. Control mice received control rat IgG. For in vivo
depletion of CD8
þ T cells, mice received an anti-CD8-depleting
monoclonal Ab (2.43, rat IgG, 200mg), which was intraperitoneally
injected 6, 3, and 1 day before tumour implantation and weekly
thereafter as previously described (Sho et al, 2002). Gemcitabine
was intraperitoneally given at a dose of 0.8mg per body, every 3
days, 5 times in total. The doses were determined on the basis of
our preliminary experiments. Tumour volume was calculated
according to the formula V¼A B
2/2 (mm
3), where A is the
largest diameter (mm) and B is the smallest diameter (mm). At 4
weeks after tumour establishment, the mice were killed and
tumours were removed for further analysis.
Cell viability analysis
Cell viability was determined using the Cell-titer 96 aqueous one
solution cell proliferation assay kit, according to the instruction
manual (Promega Corporation, Madison, WI, USA). Briefly,
aliquots of 1 10
3 cells per well were cultured in 96-well plates
with MJ18 or control IgG for 72h. Antibody was used at a
concentration of 1 or 10mgml
 1. Cell-titer 96 aqueous one solution
was added to each well and incubated for an additional 1h. The
absorbance at 490nm was recorded with a 96-well plate reader.
Each experiment was performed in triplicate and repeated at least
thrice.
Statistical analysis
Results were expressed as mean values±standard error, and
Student’s t-test was used for evaluating statistical significance.
A value less than 0.05 (Po0.05) was considered for statistical
significance.
RESULTS
B7-H3 expression in human pancreatic cancer
First, we examined the expression of B7-H3 on 59 pancreatic
cancer tissues by immunohistochemistry. Positive staining was
seen both on the cell membrane and in the cytoplasm of cancer
cells in 55 patients (93.2%), whereas only 4 patients (6.8%) had no
staining for B7-H3 (Figure 1). In non-cancer tissues, some islet
cells were also positive for B7-H3. We then compared the relative
expression of B7-H3 between pancreatic cancer and non-cancer
tissues using available frozen tissues by quantitative real-time
PCR. The B7-H3 expression in cancerous pancreatic tissues was
significantly higher than in non-cancerous or normal pancreatic
tissues (cancer vs non-cancer, Po0.001; cancer vs normal
pancreas, P¼0.008; non-cancer vs normal pancreas, N.S.)
(Figure 2A). Furthermore, the B7-H3 expression of cancer tissue
Figure 1 Immunohistochemical staining of human pancreatic cancer
tissue for B7-H3. Positive staining was seen on the cell membrane and in
the cytoplasm of cancer cells in almost all patients. Representative tissue of
no staining (A), weak intensity (B), and strong intensity (C) for B7-H3
expression in pancreatic cancer was shown. Original magnification,  100.
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swas consistently higher than that of non-cancer tissue in each
individual pancreatic cancer patient (Figure 2B). These data
suggested that B7-H3 might have some effect and may be a
potential target for immunotherapy in pancreatic cancer.
Correlation between B7-H3 expression and pathological
findings
B7-H3 was positively stained in over 90% of pancreatic cancer
patients. In these 55 positive tissues, it was homogeneously
expressed in almost all pancreatic cancer cells in each examined
tumour section. Therefore, all specimens were classified into two
groups according to staining intensity as follows: 39 tumours with
strong staining and 20 tumours with weak or no staining (Figure 1).
We evaluated the correlation of the B7-H3 expression with various
clinicopathological data. We found that tumours with a strong
intensity of B7-H3 expression had more common lymph node
metastasis (P¼0.020) and advanced pathological stage (P¼0.040)
(Table 1). These data suggested that B7-H3 expression might be
functionally important in tumour progression and metastasis in
pancreatic cancer. In this study, there was no significant difference
in the post-operative prognosis between strong and weak intensity
of tumour B7-H3 expression.
Therapeutic efficacy of anti-B7-H3 mAb in pancreatic
cancer
Towards a clinical application of targeting the B7-H3 pathway,
we examined the therapeutic efficacy of anti-B7-H3-blocking
mAb in pancreatic cancer. To this end, we used a murine
pancreatic cancer model using PAN02, a murine pancreatic
adenocarcinoma. We confirmed B7-H3 expression in PAN02 by
RT-PCR and flow cytometry (data not shown). The anti-B7-H3
mAb, MJ18, treatment induced substantial anti-tumour effect
in vivo and significantly inhibited tumour growth (tumour volume
at 2 weeks: anti-B7-H3 mAb, n¼7, 23.6±12.2mm
3; control, n¼5,
69.1±14.4mm
3; P¼0.036; tumour volume at 4 weeks: anti-B7-H3
mAb, n¼10, 144.6±13.3mm
3; control, n¼9, 320.4±36.1mm
3;
P¼0.0002) (Figure 3). To analyse the underlying mechanisms, we
first tested in vitro effect of MJ18 on PAN02. A total of 1000
PAN02s were co-cultured with MJ18. Control rat IgG was used as a
control. The survival rate of PAN02 was determined by MTS assay.
As a result, B7-H3 blockade did not have any direct effect on
cancer cell growth in vitro (Figure 4). We then evaluated tumour-
infiltrating T cells after mAb treatment. At 2 weeks after tumour
implantation, CD8
þ, but not CD4
þ, T cells in tumours treated
with MJ18 were significantly more than that in controls, as
indicated by real-time PCR (CD8
þ T cells, n¼3, P¼0.024; CD4
þ
T cells, n¼3, N.S.; controls, n¼4) (Figure 5A). This was
confirmed by immunohistochemical analysis on pancreatic cancer
tissues at 4 weeks after tumour implantation. There was a more
profound infiltration of CD8
þ T cells into the tumour treated with
B7-H3 blockade compared with controls (anti-B7-H3 mAb, n¼5,
134.2±11.2; control, n¼5, 50.5±11.2, Po0.001) (Figure 5B
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Figure 2 Comparison of B7-H3 expression between cancer and non-cancer tissues of the pancreas. (A) The cumulative B7-H3 expression in cancer
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Po0.0001; cancer vs normal pancreas, P¼0.0078; non-cancer vs normal pancreas, N.S.). (B) The expression in cancer tissue is consistently higher than that
in non-cancer tissue of individual pancreatic cancer patients.
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
24 0
Weeks after tumour implantation
Control IgG
Anti-B7-H3 mAb
400
350
300
250
200
150
100
50
0
Figure 3 Therapeutic efficacy of B7-H3 blockade in murine pancreatic
cancer. The effect of B7-H3 blockade on pancreatic cancer was examined
in vivo. PAN02 was orthotopically implanted in the pancreas of syngeneic
C57BL/6 mice. B7-H3 blockade significantly inhibited tumour growth
compared with controls. (P¼0.036 and 0.0002 at 2 and 4 weeks,
respectively).
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sand C). Data indicated that B7-H3 blockade promoted the
infiltrations of CD8
þ T cells into tumours, thereby resulting in
tumour growth inhibition. Furthermore, to confirm the require-
ment of CD8
þ T cells for the anti-tumour effect of B7-H3
blockade, we used an in vivo depletion experiment. As a result, the
depletion of CD8
þ T cells completely abolished the effect of anti-
B7-H3 mAb on murine pancreatic cancer (tumour volume at 4
weeks: anti-B7-H3 mAb, n¼5, 255.4±21.4mm
3; control, n¼5,
240.1±21.4mm
3; N.S.) (Figure 6). Therefore, data clearly indicated
that CD8 T cells are effectors and are also essential for the anti-
tumour effect of B7-H3 blockade.
Synergy between B7-H3 blockade and conventional
chemotherapy
Finally, we evaluated the combination of conventional chemother-
apy with B7-H3 blockade in pancreatic cancer. We used
gemcitabine, which is currently the standard chemotherapeutic
agent for pancreatic cancer. The treatment with gemcitabine alone
resulted in significant inhibition of tumour growth (n¼5,
108.6±9.3mm
3, P¼0.0011 compared with controls). The com-
bined treatment of gemcitabine and B7-H3 blockade showed a
substantial synergistic anti-tumour effect on pancreatic cancer
(n¼5, 27.1±4.9mm
3, Po0.0001 compared with gemcitabine
alone or B7-H3 blockade alone) (Figure 7). There were no overt
toxicity and death in mice during and after treatment.
DISCUSSION
Although the cancer-related death rates of various malignancies
have been declining because of improvements in early detection
and treatment, the overall pancreatic cancer mortality rate is still
extremely high (Jemal et al, 2007). To improve patient survival,
novel strategies need to be developed. Immunotherapy is an
attractive strategy and may provide a breakthrough in the
treatment of pancreatic cancer. However, the clinical response
rates of current immunotherapies are limited, presumably because
of tumour immune escape mechanisms (Laheru and Jaffee, 2005;
Plate, 2007). Thus, to elicit sufficient tumour-specific T-cell
responses, it is necessary to overcome tumour immune evasion.
One of the strategies may be targeting T-cell-inhibitory pathways,
including B7/CTLA-4 and PD-L/PD-1 (Dong et al, 2002; Curiel
et al, 2003; Ohigashi et al, 2005; Nomi et al, 2007). However, the
effect of human CTLA-4-blocking antibody is likely to be limited
in current clinical trials (Downey et al, 2007; Hodi et al, 2008).
Therefore, further attempts to identify specific negative regulatory
molecules for cancer immunotherapy may be needed. We were
intrigued with a new member of the B7 family, B7-H3, as a
potential negative molecule for T-cell activation in tumour
immunity. We first examined the tumour B7-H3 expression in
human pancreatic cancer, and found that tumour B7-H3 expres-
sion was consistently high in comparison with non-cancer tissue
and significantly correlated with lymph node metastasis and
advanced pathological stage. These clinical data suggested that
tumour B7-H3 might function as a negative regulator in pancreatic
cancer. This might be consistent with several previous reports in
other malignancies, including lung and prostate cancers (Castri-
coni et al, 2004; Sun et al, 2006; Roth et al, 2007; Zang et al, 2007).
However, there was no significant difference in post-operative
prognosis as a result of tumour B7-H3 expression. The reason for
this discrepancy may lie, in part, in the development of adjuvant
chemotherapy. In fact, the post-operative prognosis in our
department is much better because of aggressive chemotherapy
for post-operative recurrence. On the other hand, conflicting
observations were shown in a clinical study of gastric cancer and in
a study of a murine colon cancer model. These indicate that high
intra-tumour B7-H3 expression correlated with better prognosis in
gastric cancer (Wu et al, 2006), and the introduction of B7-H3 into
colon cancer cells leads to a reduction in tumour metastasis and
tumour regression (Lupu et al, 2006, 2007). To clarify these
discrepancies in tumour B7-H3 expression, a key issue may be to
identify unknown receptors for B7-H3. It has been reported that
soluble B7-H3 protein binds a putative counter-receptor on
activated T cells that is distinct from CD28 and CTLA-4 (Chapoval
et al, 2001; Sun et al, 2002). Furthermore, two distinct receptors
have been assumed to explain the duality of the stimulatory and
inhibitory functions imparted by B7-H3 (Roth et al, 2007).
Hashiguchi et al, 2008 have recently reported that the triggering
receptor expressed on myeloid cells, (TREM)-like Transcript 2
(TLT-2, TREML2), is a receptor for B7-H3. They showed that the
interaction of B7-H3 with TLT-2 on T cells enhanced T-cell
activation. B7-H3 may use another inhibitory receptor besides
TLT-2. Therefore, depending on the affinity of differential
receptors, tumour-associated B7-H3 may have distinct functional
effects in vivo. A high-level expression of B7-H3 by transfection
may engage TLT-2 to enhance T-cell responses. By contrast, other
cancers with relatively low or physiological levels of B7-H3
expression may engage an inhibitory receptor (Lupu et al, 2006,
2007; Yi and Chen, 2009). Further investigations for the
identification of receptors are clearly warranted to elucidate the
physiological and pathological functions of B7-H3 in various
conditions.
On the basis of our clinical data, we then investigated the
therapeutic efficacy of blocking the B7-H3 pathway in pancreatic
cancer towards future application. We used a murine orthotopic
pancreatic cancer model. We found several important observa-
tions. First, anti-B7-H3-blocking mAb had a significant anti-
tumour effect on tumour growth in vivo. This anti-tumour effect
was not observed in vitro, suggesting that mAb had no direct effect
on cancer cell growth. Furthermore, we observed that CD8
þ T-cell
infiltration into tumours was promoted by B7-H3 blockade.
Furthermore, the in vivo depletion indicated that CD8
þ T cells
are required for the anti-tumour effect of B7-H3 blockade. Taken
together, these data suggested that the B7-H3 pathway might
critically regulate the growth of pancreatic cancer in vivo through
the negative interaction between tumours and tumour-reactive
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Figure 4 Effect of anti-B7-H3 mAb on pancreatic cancer in vitro. A total
of 1000 murine pancreatic cancer cells, PAN02s, were co-cultured with
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have any direct effect on cancer cell growth in vitro, as determined by MTS
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sCD8
þ T cells. Although some islet cells were also positive for B7-
H3, blood sugar levels were consistently normal and mice were
healthy after mAb treatment. Second, more importantly, our data
indicated that the combination of gemcitabine with B7-H3
blockade exerted a synergistic anti-tumour effect on pancreatic
cancer. In clinical settings, gemcitabine is still currently the best
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þ, but not CD4
þ, T cells in tumours treated with anti-B7-H3 mAb
were more abundant than in controls (P¼0.024), as shown by quantitative real-time PCR. (B) Immunohistochemical analysis of CD8
þ T cells in tumours
treated with anti-B7-H3 mAb or control IgG (Po0.001). (C) Representative immunohistochemical staining of tumour-infiltrating CD8
þ T cells. Original
magnification,  200. A more profound infiltration of CD8
þ T cells was observed in the tumour treated with anti-B7-H3 mAb compared with controls.
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Figure 7 Combination of B7-H3 blockade with gemcitabine. Treatment
with gemcitabine (GEM) alone resulted in a significant inhibition of tumour
growth (P¼0.0011). Furthermore, the combined treatment with gemcita-
bine and B7-H3 blockade showed a substantial synergistic anti-tumour effect
(Po0.0001 compared with gemcitabine alone or B7-H3 blockade alone).
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streatment available for pancreatic cancer (Burris et al, 1997; Li
et al, 2004; Hochster et al, 2006; Oettle et al, 2007). However, the
effect of gemcitabine alone is limited and most patients develop
resistance to the therapy. Therefore, gemcitabine, in combination
with other approaches, is currently under investigation (Hochster
et al, 2006). Chemotherapy and immunotherapy have usually been
regarded as unrelated or potentially antagonistic forms of therapy
(Lake and Robinson, 2005). This is because most chemotherapies
kill target cells by apoptosis and similarly induce cell death of
activated T cells recognising tumour antigen. In addition,
lymphopenia is a common side effect of many anti-cancer drugs
and this has been assumed to be detrimental to sufficient anti-
tumour immune response. On the other hand, a number of studies
have showed that chemotherapy could synergise with immu-
notherapy under some circumstances. In fact, it has been reported
that gemcitabine reduces myeloid-derived suppressor cells,
accompanied by an increase in the anti-tumour activity of CD8
þ
T cells and activated NK cells (Suzuki et al, 2005). In addition,
several previous animal studies have shown a synergistic anti-
tumour effect of gemcitabine with certain immunotherapies,
including cytokines, monoclonal antibodies, and vaccines (Nomi
et al, 2007). Thus, gemcitabine is a candidate chemotherapeutic
agent for the combination therapy with immunotherapy.
Although further studies are required to determine the underlying
mechanisms in a synergistic effect between gemcitabine and B7-H3
blockade, our data may be clinically important and support future
application of B7-H3 blockade for the treatment of pancreatic
cancer.
In conclusion, we showed for the first time that B7-H3 is
abundantly expressed in human pancreatic cancer and it has
clinical significance. Furthermore, our data also indicated that
B7-H3 is a potential target for immunotherapy against pancreatic
cancer. This study may provide the rationale for developing a
novel cancer therapy for this fatal malignant disease.
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